Uridine transport in human erythrocytes: data from normal subjects and from patients with renal failure. 1991

F C Fervenza, and D Meredith, and J C Ellory, and B M Hendry
Renal Unit, Churchill Hospital, Headington, Oxford.

Erythrocyte uridine transport has been studied in eight normal individuals and eight patients on haemodialysis for chronic renal failure. The initial rate of zero-trans uridine influx at 37 degrees C has been measured as a function of extracellular uridine concentration using [14C]-labelled uridine. The results are consistent with Michaelis-Menten kinetics. In normal humans the mean Vmax for uridine influx was 32.8 +/- 6.4 mumol (1 cells)-1 s-1 (mean +/- S.D.) and the mean Km was 190 +/- 12.3 microM. The measurements made in renal failure patients were not significantly different (mean Vmax 30.1 +/- 7.1 mumol (1 cells)-1 s-1, mean Km, 185 +/- 13.2 microM). These results are discussed with reference to the reported data on uridine transport in human erythrocytes at temperatures between 4 and 35 degrees C; it is suggested that zero-trans uridine influx shows a decrease in temperature dependence above 25 degrees C. The Vmax for zero-trans uridine influx at 37 degrees C in normal erythrocytes represents a turnover number for the nucleoside transporter of 180 uridine molecules per second.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D004910 Erythrocyte Membrane The semi-permeable outer structure of a red blood cell. It is known as a red cell 'ghost' after HEMOLYSIS. Erythrocyte Ghost,Red Cell Cytoskeleton,Red Cell Ghost,Erythrocyte Cytoskeleton,Cytoskeleton, Erythrocyte,Cytoskeleton, Red Cell,Erythrocyte Cytoskeletons,Erythrocyte Ghosts,Erythrocyte Membranes,Ghost, Erythrocyte,Ghost, Red Cell,Membrane, Erythrocyte,Red Cell Cytoskeletons,Red Cell Ghosts
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001693 Biological Transport, Active The movement of materials across cell membranes and epithelial layers against an electrochemical gradient, requiring the expenditure of metabolic energy. Active Transport,Uphill Transport,Active Biological Transport,Biologic Transport, Active,Transport, Active Biological,Active Biologic Transport,Transport, Active,Transport, Active Biologic,Transport, Uphill
D014529 Uridine A ribonucleoside in which RIBOSE is linked to URACIL. Allo-Uridine,Allouridine,Allo Uridine

Related Publications

F C Fervenza, and D Meredith, and J C Ellory, and B M Hendry
January 1982, Nephron,
F C Fervenza, and D Meredith, and J C Ellory, and B M Hendry
April 1989, Clinical science (London, England : 1979),
F C Fervenza, and D Meredith, and J C Ellory, and B M Hendry
July 1975, Clinical pharmacology and therapeutics,
F C Fervenza, and D Meredith, and J C Ellory, and B M Hendry
October 1992, Minerva medica,
F C Fervenza, and D Meredith, and J C Ellory, and B M Hendry
June 1972, The New Zealand medical journal,
F C Fervenza, and D Meredith, and J C Ellory, and B M Hendry
April 1968, The Journal of clinical investigation,
F C Fervenza, and D Meredith, and J C Ellory, and B M Hendry
July 2004, Renal failure,
F C Fervenza, and D Meredith, and J C Ellory, and B M Hendry
June 1972, Canadian journal of biochemistry,
F C Fervenza, and D Meredith, and J C Ellory, and B M Hendry
January 1980, The Journal of antimicrobial chemotherapy,
F C Fervenza, and D Meredith, and J C Ellory, and B M Hendry
December 1977, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!